Related Experiment Video
Updated: Nov 19, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Cancer of Unknown Primary in the Molecular Era
Shumei Kato1, Ahmed Alsafar1, Vighnesh Walavalkar2
1Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA.
Abstract:
Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation sequencing has revealed genomic alterations that can be targeted in selected cases, suggesting that CUP represents a unique malignancy in which the genomic aberrations may be integral to the diagnosis. Recent trials focusing on tailored combination therapy matched to the genomic alterations in each cancer are providing new avenues of clinical investigation. Here, we discuss recent findings on molecular aberrations in CUP and how the genomic and immune landscape can be leveraged to optimize therapy.
Insights
Cancer of unknown primary (CUP) is a rare cancer presenting as metastasis without a clear origin. Genomic analysis reveals targeted treatment opportunities, improving patient outcomes by matching therapies to specific molecular aberrations.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Cancer of unknown primary (CUP) is a rare malignancy characterized by metastatic disease without an identifiable primary site.
- Current treatments based on presumed tissue of origin offer limited survival benefits compared to empiric chemotherapy.
Purpose of the Study:
- To review recent findings on molecular aberrations in CUP.
- To explore how genomic and immune profiling can guide optimized therapy for CUP patients.
Main Methods:
- Review of recent literature on cancer of unknown primary.
- Analysis of next-generation sequencing data identifying genomic alterations in CUP.
- Discussion of clinical trials investigating targeted therapies.
Main Results:
- Next-generation sequencing has identified specific genomic alterations in CUP.
- These aberrations suggest CUP is a distinct malignancy where genomic profile is key for diagnosis.
- Targeted therapies matched to genomic alterations show promise in clinical investigations.
Conclusions:
- Genomic profiling is crucial for understanding and diagnosing cancer of unknown primary.
- Leveraging the genomic and immune landscape offers new therapeutic strategies for CUP.
- Tailored combination therapies based on molecular aberrations represent a promising direction for CUP treatment.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:12What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...